Free tool
FAERS Monitor: Vybrique
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210858 or its brand name (Vybrique, Sildenafil Citrate). Reports on generic versions are filed under their own applications.
Reports
58,697
Serious
42,844
73% of reports
Hospitalization
25,676
Death reported
8,676
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea8,090
- headache6,073
- diarrhoea4,714
- nausea4,199
- fatigue4,055
- death4,027
- dizziness3,520
- drug ineffective3,249
- cough3,224
- pneumonia2,743
- hypotension2,493
- vomiting2,491
- off label use2,399
- malaise2,253
- pain2,116
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 124 |
| 2005 | 186 |
| 2006 | 393 |
| 2007 | 174 |
| 2008 | 234 |
| 2009 | 295 |
| 2010 | 416 |
| 2011 | 457 |
| 2012 | 1,172 |
| 2013 | 1,589 |
| 2014 | 2,307 |
| 2015 | 2,706 |
| 2016 | 3,100 |
| 2017 | 3,839 |
| 2018 | 4,222 |
| 2019 | 5,480 |
| 2020 | 5,142 |
| 2021 | 4,407 |
| 2022 | 4,449 |
| 2023 | 4,803 |
| 2024 | 4,904 |
| 2025 | 5,073 |
| 2026 | 3,225 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,995,462 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dyspnoeaSignal | 8,090 | 5.2 | 5.1 | 27,643 |
| hypotensionSignal | 2,493 | 4.5 | 4.3 | 6,756 |
| coughSignal | 3,224 | 4.2 | 4.0 | 7,737 |
| headacheSignal | 6,073 | 3.5 | 3.4 | 11,039 |
| pneumoniaSignal | 2,743 | 3.1 | 2.9 | 3,812 |
| diarrhoeaSignal | 4,714 | 2.6 | 2.6 | 4,870 |
| dizzinessSignal | 3,520 | 2.5 | 2.5 | 3,340 |
| nausea | 4,199 | 1.9 | 1.9 | 1,868 |
| vomiting | 2,491 | 1.9 | 1.8 | 1,086 |
| fatigue | 4,055 | 1.9 | 1.8 | 1,697 |
| malaise | 2,253 | 1.8 | 1.8 | 885 |
| death | 4,027 | 1.7 | 1.6 | 1,145 |
| pain | 2,116 | 1.2 | 1.2 | 97 |
| off label use | 2,399 | 1.0 | 0.9 | 1 |
| drug ineffective | 3,249 | 0.9 | 0.9 | 53 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.